Methods for predicting diabetes phase iii efficacy outcome from early data: Superior performance obtained using longitudinal approaches

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 7, 2014, Pages

  Moller J B ^a   Kristensen, N R ^a   Klim, S ^a   Karlsson, M O ^b   Ingwersen, S H ^a   Kjellsson, M C ^b  

^a NOVO NORDISK A S   (Denmark)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; ROSIGLITAZONE;

ANALYTIC METHOD; ARTICLE; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; ERYTHROCYTE LIFESPAN; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STEADY STATE; TREATMENT OUTCOME;

EID: 84905399898     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.20     Document Type: Article

References (25)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36, 1033-1046 (2013).
2. Paul, S.M. et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
3. Danaei, G. et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-Years and 2.7 million partipants. Lancet 378, 31-40 (2011).
4. Roden, M. Clinical Diabetes Research: Methods and Techniques (John Wiley &Sons, Chichester, 2007), 387-392.
5. Schrot, R.J., Patel, K.T. &Foulis, P. Evaluation of inaccuracies in the measurement of glycemia in the laboraty, by glucose meters, and through measurement of hemoglobin A1c. Clinical Diabetes 25, 43-49 (2007).
6. Frank, E.A., Shubha, M.C. &D'Souza, C.J.M. Blood glucose determination: Plasma or serum? J. Clin. Lab. Anal. 26, 317-320 (2012).
7. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-Dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986 (1993).
8. Lind, M., Odén, A., Fahlén, M. &Eliasson, B. The true value of HbA1c as a predictor of diabetic complications: Simulations of HbA1c values. PLoS One 4, e4412 (2009).
9. Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention (U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), Rockville p. 12, (February 2008).
10. Guideline on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus (Committee for Medicinal Products for Human Use (CHMP), CPMP/EWP/1080/00 Rev. 1, EMA, London, p. 7, (14 May 2012).
11. Aleyassine, H., Gardiner, R.J., Tonks, D.B. &Koch, P. Glycosylated hemoglobin in diabetes mellitus: Correlations with fasting plasma glucose, serum lipids, and glycosuria. Diabetes Care 3, 508-514 (1980).
12. Karl, D., Zhou, R., Vlajnic, A. &Riddle, M. Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: A pooled analysis. Diabet. Med. 29, 933-936 (2012).
13. Rohlfing, C.L., Wiedmeyer, H.M., Little, R.R., England, J.D., Tennill, A. &Goldstein, D.E. Defining the relationship between plasma glucose and HbA(1c): Analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 25, 275-278 (2002).
14. Nathan, D.M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D. &Heine, R.J. Translating the A1C assay into estimated average glucose values. Diabetes Care 31, 1473-1478 (2008).
15. Monnier, L., Lapinski, H. &Colette, C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26, 881-885 (2003).
16. Monnier, L., Colette, C. &Owens, D. Postprandial and basal glucose in type 2 diabetes: Assessment and respective impacts. Diabetes Technol. Ther. 13 (suppl. 1), S25-S32 (2011).
17. Samtani, M.N. Simple pharmacometric tools for oral anti-Diabetic drug development: Competitive landscape for oral non-insulin therapies in type 2 diabetes. Biopharm. Drug Dispos. 31, 162-177 (2010).
18. Lledó-Garcia, R., Mazer, N.A. &Karlsson, M.O. A semi-Mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects. J. Pharmacokinet. Pharmacodyn. 40, 129-142 (2013).
19. Møller, J.B. et al. Longitudinal modeling of the relationship between mean plasma glucose and HbA1c following antidiabetic treatments. CPT Pharmacometrics Syst. Pharmacol. 2, e82 (2013).
20. Rosenstock, J., Davies, M., Home, P.D., Larsen, J., Koenen, C. &Schernthaner, G. A randomised, 52-Week, treat-To-Target trial comparing insulin detemir with insulin glargine when administered as add-On to glucose-Lowering drugs in insulin-Naive people with type 2 diabetes. Diabetologia 51, 408-416 (2008).
21. Raskin, P. et al. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 28, 260-265 (2005).
22. Zinman, B. et al.; LEAD-4 Study Group. Efficacy and safety of the human glucagon-Like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32, 1224-1230 (2009).
23. Nauck, M. et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32, 84-90 (2009).
24. Riddle, M., Umpierrez, G., DiGenio, A., Zhou, R. &Rosenstock, J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 34, 2508-2514.
25. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type II diabetes (UKPDS 34). Lancet 352, 854-865 (1998